New data from the Primary Rituximab And Maintenance study provide the strongest support for the use of rituximab maintenance in patients with follicular lymphoma. However, further considerations of cost, inconvenience, toxic effects, efficacy of retreatment and lack of survival benefit should focus future clinical research on more-effective induction strategies.
Related Articles
Senza categoria
Newsround
Impact Factor
Is rituximab maintenance therapy useful following rituximab salvage in refractory or relapsed follicular lymphoma?
Impact Factor
Leave a Reply